These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Mechanism of action of 2-methoxyestradiol: new developments. Mooberry SL Drug Resist Updat; 2003 Dec; 6(6):355-61. PubMed ID: 14744499 [TBL] [Abstract][Full Text] [Related]
3. Recent Advances in chemistry and pharmacology of 2-methoxyestradiol: An anticancer investigational drug. Kumar BS; Raghuvanshi DS; Hasanain M; Alam S; Sarkar J; Mitra K; Khan F; Negi AS Steroids; 2016 Jun; 110():9-34. PubMed ID: 27020471 [TBL] [Abstract][Full Text] [Related]
4. Role of 2-methoxyestradiol, an Endogenous Estrogen Metabolite, in Health and Disease. Parada-Bustamante A; Valencia C; Reuquen P; Diaz P; Rincion-Rodriguez R; Orihuela PA Mini Rev Med Chem; 2015; 15(5):427-38. PubMed ID: 25723461 [TBL] [Abstract][Full Text] [Related]
5. The effect of exchanging various substituents at the 2-position of 2-methoxyestradiol on cytotoxicity in human cancer cell cultures and inhibition of tubulin polymerization. Cushman M; Mohanakrishnan AK; Hollingshead M; Hamel E J Med Chem; 2002 Oct; 45(21):4748-54. PubMed ID: 12361402 [TBL] [Abstract][Full Text] [Related]
7. Structure activity analysis of 2-methoxyestradiol analogues reveals targeting of microtubules as the major mechanism of antiproliferative and proapoptotic activity. Chua YS; Chua YL; Hagen T Mol Cancer Ther; 2010 Jan; 9(1):224-35. PubMed ID: 20053769 [TBL] [Abstract][Full Text] [Related]
8. Synthesis and Pharmacological Effects of the Anti-Cancer Agent 2-Methoxyestradiol. Solum EJ; Akselsen ØW; Vik A; Hansen TV Curr Pharm Des; 2015; 21(38):5453-66. PubMed ID: 26429718 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and structure-activity relationships of 16-modified analogs of 2-methoxyestradiol. Agoston GE; Shah JH; Lavallee TM; Zhan X; Pribluda VS; Treston AM Bioorg Med Chem; 2007 Dec; 15(24):7524-37. PubMed ID: 17910916 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and antimitotic activity of novel 2-methoxyestradiol analogs. Part III. Rao PN; Cessac JW; Boyd JW; Hanson AD; Shah J Steroids; 2008 Feb; 73(2):171-83. PubMed ID: 18155739 [TBL] [Abstract][Full Text] [Related]
11. New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent. Mooberry SL Curr Opin Oncol; 2003 Nov; 15(6):425-30. PubMed ID: 14624224 [TBL] [Abstract][Full Text] [Related]
13. The physiological estrogen metabolite 2-methoxyestradiol reduces tumor growth and induces apoptosis in human solid tumors. Schumacher G; Neuhaus P J Cancer Res Clin Oncol; 2001 Jul; 127(7):405-10. PubMed ID: 11469676 [TBL] [Abstract][Full Text] [Related]
14. A short, economical synthesis of 2-methoxyestradiol, an anticancer agent in clinical trials. Hou Y; Meyers CY; Akomeah M J Org Chem; 2009 Aug; 74(16):6362-4. PubMed ID: 19610601 [TBL] [Abstract][Full Text] [Related]
15. 2-Methoxyestradiol and analogs as novel antiproliferative agents: analysis of three-dimensional quantitative structure-activity relationships for DNA synthesis inhibition and estrogen receptor binding. Hughes RA; Harris T; Altmann E; McAllister D; Vlahos R; Robertson A; Cushman M; Wang Z; Stewart AG Mol Pharmacol; 2002 May; 61(5):1053-69. PubMed ID: 11961123 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic promises of 2-methoxyestradiol and its drug disposition challenges. Verenich S; Gerk PM Mol Pharm; 2010 Dec; 7(6):2030-9. PubMed ID: 20831190 [TBL] [Abstract][Full Text] [Related]
18. Synthesis of B-ring homologated estradiol analogues that modulate tubulin polymerization and microtubule stability. Wang Z; Yang D; Mohanakrishnan AK; Fanwick PE; Nampoothiri P; Hamel E; Cushman M J Med Chem; 2000 Jun; 43(12):2419-29. PubMed ID: 10882369 [TBL] [Abstract][Full Text] [Related]
19. Neuronal nitric oxide synthase induction in the antitumorigenic and neurotoxic effects of 2-methoxyestradiol. Gorska M; Kuban-Jankowska A; Zmijewski MA; Gorzynik M; Szkatula M; Wozniak M Molecules; 2014 Aug; 19(9):13267-81. PubMed ID: 25170949 [TBL] [Abstract][Full Text] [Related]
20. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Dahut WL; Lakhani NJ; Gulley JL; Arlen PM; Kohn EC; Kotz H; McNally D; Parr A; Nguyen D; Yang SX; Steinberg SM; Venitz J; Sparreboom A; Figg WD Cancer Biol Ther; 2006 Jan; 5(1):22-7. PubMed ID: 16357512 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]